Status:
TERMINATED
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19
Lead Sponsor:
Azienda Ospedaliero, Universitaria Pisana
Conditions:
COVID
SARS-CoV 2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, are under investigation, but the antiviral efficacy of these drugs is not yet known. The use of convalescent p...
Detailed Description
This is a multicenter prospective randomized open-label clinical trials. Patients with pneumonia due to SARS-CoV-2 will be included and randomized to receive or not convalescent plasma. Convalescent ...
Eligibility Criteria
Inclusion
- Any gender
- Age \> 18 years on day of signing informed consent
- Informed written consent for participation in the study
- Virological diagnosis of SARS-CoV-2 infection (real-time PCR)
- Hospitalized due to clinical instrumental diagnosis of pneumonia
- PaO2/FiO2 ratio 200-350
Exclusion
- mechanical ventilation (both invasive and non-invasive)
- PaO2/FiO2\<200
- known hypersensitivity to immunoglobulin or blood components
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04393727
Start Date
May 1 2020
End Date
September 30 2020
Last Update
November 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy, 56124